Diet- and valproate-induced transient hyperammonemia: effect of L-carnitine. 1997

B E Gidal, and C M Inglese, and J F Meyer, and M E Pitterle, and J Antonopolous, and R S Rust
School of Pharmacy, University of Wisconsin, Madison, USA.

Hyperammonemia is an adverse effect of valproate (VPA) treatment. In particular, transient hyperammonemia has been reported to occur in VPA-treated patients after protein-rich meals. This phenomenon may occur secondary to a VPA-mediated carnitine insufficiency. We sought to confirm that protein ingestion would result in transient hyperammonemia and to determine whether supplementation with L-carnitine would prevent this effect. We studied the effect of consumption of a standardized protein-rich meal (45 g protein) before (phase I) and after (phase II) administration of L-carnitine 50 mg/kg/day for 7 days in 11 epileptic children (13.3 +/- 2.3 years of age) receiving VPA. Venous blood was obtained during fasting (baseline) and at 2 and 4 hours after the protein-rich meal for analysis of ammonia (NH3), and VPA concentrations. Mean VPA trough concentrations did not differ significantly at any time. After protein ingestion, 2-hour NH3 concentration increased by 86% (P < .05) from baseline in phase I as compared with a 38% increase in phase II. In both phases I and II, 4-hour NH3 concentrations decreased toward baseline values. We conclude that (1) modest protein ingestion can result in significant transient increases in NH3 in VPA-treated children, (2) significant increases may occur in patients with normal fasting NH3 concentrations, (3) these increases can be significantly attenuated by L-carnitine supplementation, and (4) these changes do not appear to be related to changes in VPA concentration.

UI MeSH Term Description Entries
D008297 Male Males
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002331 Carnitine A constituent of STRIATED MUSCLE and LIVER. It is an amino acid derivative and an essential cofactor for fatty acid metabolism. Bicarnesine,L-Carnitine,Levocarnitine,Vitamin BT,L Carnitine
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004032 Diet Regular course of eating and drinking adopted by a person or animal. Diets
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

B E Gidal, and C M Inglese, and J F Meyer, and M E Pitterle, and J Antonopolous, and R S Rust
January 1984, World review of nutrition and dietetics,
B E Gidal, and C M Inglese, and J F Meyer, and M E Pitterle, and J Antonopolous, and R S Rust
January 2022, International journal of physiology, pathophysiology and pharmacology,
B E Gidal, and C M Inglese, and J F Meyer, and M E Pitterle, and J Antonopolous, and R S Rust
June 1988, Biochemical pharmacology,
B E Gidal, and C M Inglese, and J F Meyer, and M E Pitterle, and J Antonopolous, and R S Rust
June 1987, The Kobe journal of medical sciences,
B E Gidal, and C M Inglese, and J F Meyer, and M E Pitterle, and J Antonopolous, and R S Rust
June 1990, The Japanese journal of psychiatry and neurology,
B E Gidal, and C M Inglese, and J F Meyer, and M E Pitterle, and J Antonopolous, and R S Rust
February 2002, Neurology,
B E Gidal, and C M Inglese, and J F Meyer, and M E Pitterle, and J Antonopolous, and R S Rust
May 2001, Neurology,
B E Gidal, and C M Inglese, and J F Meyer, and M E Pitterle, and J Antonopolous, and R S Rust
January 1984, FEBS letters,
B E Gidal, and C M Inglese, and J F Meyer, and M E Pitterle, and J Antonopolous, and R S Rust
March 2014, Medicina intensiva,
B E Gidal, and C M Inglese, and J F Meyer, and M E Pitterle, and J Antonopolous, and R S Rust
March 1982, Annals of neurology,
Copied contents to your clipboard!